Management of primary intraocular lymphoma |
| |
Authors: | Stella K Kim Chi-Chao Chan Dana J Wallace |
| |
Institution: | (1) University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, #443, 77030 Houston, TX, USA |
| |
Abstract: | Primary intraocular lymphoma (PIOL) is a subset of primary central nervous system lymphoma (PCNSL) in which malignant lymphoid
cells invade the retina, vitreous body, or optic nerve head. It is usually a large B-cell non-Hodgkin’s lymphoma. PIOL typically
presents as a vitritis that is unresponsive to corticosteroid therapy. Diagnosis of PIOL requires pathologic confirmation
of malignant cells in specimens of the cerebrospinal fluid, vitreous, or chorioretinal biopsies. The optimal therapy for PIOL
has yet to be determined. It is generally believed that PIOL should be treated with a combination of systemic chemotherapy,
including high-dose methotrexate and radiotherapy. However, several new developments for PIOL with central nervous system
involvement have been reported, including intrathecal therapy and autologous stem-cell transplantation. In addition, intravitreal
methotrexate has been successful in the treatment of isolated recurrent ocular disease. This article provides an overview
of treatment modalities for initial, recurrent, and relapsed PIOL. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|